NCT04434196 is a Phase 1 clinical trial of CC-99282 in Lymphoma, Non-Hodgkin, sponsored by Celgene.

Who is sponsoring NCT04434196?

NCT04434196 is sponsored by Celgene.

What drugs are being tested in NCT04434196?

Interventions in NCT04434196: CC-99282, Obinutuzumab.

What condition does NCT04434196 study?

NCT04434196 studies Lymphoma, Non-Hodgkin.

Is NCT04434196 still recruiting?

NCT04434196 is currently completed. Last updated 25 July 2024.

Last reviewed 2024-07-25 · How we verify

NCT04434196

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed Phase 1 Last updated 25 July 2024

What this trial tests

Phase 1 trial testing CC-99282 in Lymphoma, Non-Hodgkin in 16 participants. Completed in 21 May 2024.

Timeline

21 December 2020

Primary endpoint
21 May 2024

21 May 2024

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	21 December 2020
Primary completion	21 May 2024
Estimated completion	21 May 2024
Sites	15 locations across Austria, Canada, United States, Spain

Drugs / interventions tested

CC-99282 — full drug profile →
Obinutuzumab — full drug profile →

Conditions studied

Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

PROTAC targeted protein degraders: the past is prologue.
Békés M, Langley DR, Crews CM. · · 2022 · cited 2098× · PMID 35042991 · DOI 10.1038/s41573-021-00371-6
Protein degraders enter the clinic - a new approach to cancer therapy.
Chirnomas D, Hornberger KR, Crews CM. · · 2023 · cited 430× · PMID 36781982 · DOI 10.1038/s41571-023-00736-3
Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y, Ge S. · · 2022 · cited 53× · PMID 35331314 · DOI 10.1186/s13045-022-01251-1
Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J, Chen X, Lu A, Liang C. · · 2023 · cited 29× · PMID 37033156 · DOI 10.1016/j.xinn.2023.100413
TACkling Cancer by Targeting Selective Protein Degradation.
Noblejas-López MDM, Tébar-García D, López-Rosa R, Alcaraz-Sanabria A, et al · · 2023 · cited 20× · PMID 37896202 · DOI 10.3390/pharmaceutics15102442
Targeted Protein Degradation: Clinical Advances in the Field of Oncology.
Salama AKAA, Trkulja MV, Casanova E, Uras IZ. · · 2022 · cited 19× · PMID 36499765 · DOI 10.3390/ijms232315440
Mantle cell lymphoma management trends and novel agents: where are we going?
Pu JJ, Savani M, Huang N, Epner EM. · · 2022 · cited 11× · PMID 35237397 · DOI 10.1177/20406207221080743

Verify or expand the search:

Other trials of CC-99282

Trials testing the same drug.

NCT06108232 — Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma · Phase 2 · active not recruiting
NCT04884035 — Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma · Phase 1 · recruiting
NCT03930953 — A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants · Phase 1, PHASE2 · active not recruiting
NCT03310619 — A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies · Phase 1, PHASE2 · completed

Other recruiting trials for Lymphoma, Non-Hodgkin

Currently open trials in the same condition.

NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04434196 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 25 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04434196.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing